Climb Bio, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $46.7M | $14.3M | $15.4M | $26.2M | $23.3M |
| Operating expenses | $67.9M | $82.0M | $40.3M | $45.1M | $35.7M |
| Operating income | -$67.9M | -$82.0M | -$40.3M | -$45.1M | -$35.7M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$59.9M | -$73.9M | -$35.1M | -$45.2M | -$47.5M |
| Balance Sheet | |||||
| Cash and equivalents | $35.7M | $87.2M | $93.1M | $43.6M | $46.9M |
| Current assets | $105.8M | $154.9M | $110.3M | $134.4M | $148.3M |
| Total assets | $167.7M | $217.2M | $110.5M | $135.0M | $173.2M |
| Current liabilities | $7.0M | $4.9M | $2.8M | $6.1M | $6.0M |
| Total liabilities | $7.3M | $5.3M | $2.9M | $6.3M | $6.0M |
| Stockholders' equity | $160.5M | $211.9M | $107.6M | $128.7M | $167.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$54.4M | -$15.6M | -$20.6M | -$37.4M | -$36.1M |
| Depreciation and amortization | $97,000 | $0 | — | — | — |
| Stock-based compensation | $8.1M | $5.6M | $12.8M | $7.0M | $3.7M |
| Capital expenditure | $186,000 | $0 | $0 | — | — |
| Free cash flow | -$54.5M | -$15.6M | -$20.6M | — | — |
| Impairments | — | $0 | $180,000 | $0 | — |
Shares outstanding 57.3M · Free float 44.9%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.